Clinical Trial Update: A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907) [Phase 3]

View source ↗

Summary

A Phase 3 study (MK-0217-907) and its 12-month extension evaluating two investigational drugs for postmenopausal osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Investigational Drug 1 (MK-0217-907)
• Investigational Drug 2 (MK-0217-907)

Snippet

Sponsor: Organon and Co | Conditions: Osteoporosis, Postmenopausal | Phase 3 | Status: COMPLETED